Book Reviews by Gaby Hernandez
Respiratory failure secondary to surfactant deficiency is a major cause
of morbidity and mortalit... more Respiratory failure secondary to surfactant deficiency is a major cause
of morbidity and mortality in preterm infants. Surfactant therapy substantially
reduces mortality and respiratory morbidity for this population.
Secondary surfactant deficiency also contributes to acute
respiratory morbidity in late-preterm and term neonates with meconium
aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary
hemorrhage; surfactant replacement may be beneficial for these infants.
This statement summarizes the evidence regarding indications,
administration, formulations, and outcomes for surfactant-replacement
therapy. The clinical strategy of intubation, surfactant administration,
and extubation to continuous positive airway pressure and
the effect of continuous positive airway pressure on outcomes
and surfactant use in preterm infants are also reviewed.
Uploads
Book Reviews by Gaby Hernandez
of morbidity and mortality in preterm infants. Surfactant therapy substantially
reduces mortality and respiratory morbidity for this population.
Secondary surfactant deficiency also contributes to acute
respiratory morbidity in late-preterm and term neonates with meconium
aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary
hemorrhage; surfactant replacement may be beneficial for these infants.
This statement summarizes the evidence regarding indications,
administration, formulations, and outcomes for surfactant-replacement
therapy. The clinical strategy of intubation, surfactant administration,
and extubation to continuous positive airway pressure and
the effect of continuous positive airway pressure on outcomes
and surfactant use in preterm infants are also reviewed.
of morbidity and mortality in preterm infants. Surfactant therapy substantially
reduces mortality and respiratory morbidity for this population.
Secondary surfactant deficiency also contributes to acute
respiratory morbidity in late-preterm and term neonates with meconium
aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary
hemorrhage; surfactant replacement may be beneficial for these infants.
This statement summarizes the evidence regarding indications,
administration, formulations, and outcomes for surfactant-replacement
therapy. The clinical strategy of intubation, surfactant administration,
and extubation to continuous positive airway pressure and
the effect of continuous positive airway pressure on outcomes
and surfactant use in preterm infants are also reviewed.